Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.